FACTORS THAT INFLUENCE SURVIVAL RATE IN EXTRAOCULAR RETINOBLASTOMA PATIENTS AT CIPTO MANGUNKUSUMO HOSPITAL : 2018

Dwie Aprina, Julie D. Barliana, D. Yulia, R. S. Sitorus
{"title":"FACTORS THAT INFLUENCE SURVIVAL RATE IN EXTRAOCULAR RETINOBLASTOMA PATIENTS AT CIPTO MANGUNKUSUMO HOSPITAL : 2018","authors":"Dwie Aprina, Julie D. Barliana, D. Yulia, R. S. Sitorus","doi":"10.35749/fvstnp93","DOIUrl":null,"url":null,"abstract":"Introduction: Optimal therapeutic approach for extraocular retinoblastoma has not been determined. The prognosis of extraocular retinoblastoma compared with intraocular retinoblastoma remains relatively poor. The aim of our study is to describe the factors that influence the survival rate of extraocular retinoblastoma.\nMethods: A retrospective study. Patients diagnosed with extraocular retinoblastoma in Cipto Mangunkusumo Hospital, within 1 January to 31 December 2018 were reviewed for patient and tumor characteristic, ocular management, and patient survival.\nResult: During the study period, a total of  80 patients were diagnosed with retinoblastoma in our center, 41.2% had an extra-ocular extension The mean age at diagnosis was 25.57 months, with 56.7% being males. Leukocoria is the initial sign most often noticed by parents. The median lag period was 12 months. Neoadjuvant chemotherapy was performed in 96.7% of cases, that carried out an average of 3-4 cycles before enucleation/exenteration. At the end of September 2019, there were 17 deaths in our study. Overall survival was 19.82 months with a mean age of 27.6 months, whereas extraocular death time ranged from 4 months to 55 months. \nConclusion: Death was more common in patients with age at first symptom less than 24 months, bilateral retinoblastoma, lag period more than 12 months, advanced stage (IVB) and delayed therapy after proptosis more than 3 months.","PeriodicalId":165753,"journal":{"name":"Ophthalmologica Indonesiana","volume":"158 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmologica Indonesiana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35749/fvstnp93","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Optimal therapeutic approach for extraocular retinoblastoma has not been determined. The prognosis of extraocular retinoblastoma compared with intraocular retinoblastoma remains relatively poor. The aim of our study is to describe the factors that influence the survival rate of extraocular retinoblastoma. Methods: A retrospective study. Patients diagnosed with extraocular retinoblastoma in Cipto Mangunkusumo Hospital, within 1 January to 31 December 2018 were reviewed for patient and tumor characteristic, ocular management, and patient survival. Result: During the study period, a total of  80 patients were diagnosed with retinoblastoma in our center, 41.2% had an extra-ocular extension The mean age at diagnosis was 25.57 months, with 56.7% being males. Leukocoria is the initial sign most often noticed by parents. The median lag period was 12 months. Neoadjuvant chemotherapy was performed in 96.7% of cases, that carried out an average of 3-4 cycles before enucleation/exenteration. At the end of September 2019, there were 17 deaths in our study. Overall survival was 19.82 months with a mean age of 27.6 months, whereas extraocular death time ranged from 4 months to 55 months.  Conclusion: Death was more common in patients with age at first symptom less than 24 months, bilateral retinoblastoma, lag period more than 12 months, advanced stage (IVB) and delayed therapy after proptosis more than 3 months.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
影响 CIPPO MANGUNKUSUMO 医院眼外视网膜母细胞瘤患者存活率的因素 : 2018 年
简介:眼外视网膜母细胞瘤的最佳治疗方法尚未确定:眼外视网膜母细胞瘤的最佳治疗方法尚未确定。与眼内视网膜母细胞瘤相比,眼外视网膜母细胞瘤的预后仍然相对较差。我们的研究旨在描述影响眼外视网膜母细胞瘤存活率的因素:方法:回顾性研究。对2018年1月1日至12月31日期间在Cipto Mangunkusumo医院确诊的眼外视网膜母细胞瘤患者进行回顾性研究,了解患者和肿瘤特征、眼部处理和患者生存情况:研究期间,本中心共诊断出80例视网膜母细胞瘤患者,41.2%为眼外扩展,诊断时平均年龄为25.57个月,56.7%为男性。白细胞增多是家长最常注意到的初始症状。中位滞后期为 12 个月。96.7%的病例进行了新辅助化疗,平均3-4个周期后再进行眼球摘除术。截至2019年9月底,我们的研究中共有17人死亡。总生存期为19.82个月,平均年龄为27.6个月,而眼外死亡时间从4个月到55个月不等。结论:在首次出现症状年龄小于24个月、双侧视网膜母细胞瘤、滞后期超过12个月、晚期(IVB)和眼球突出后延迟治疗超过3个月的患者中,死亡更为常见。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
SURGICAL MANAGEMENT IN ESOTROPIA AT CIPTO MANGUNKUSUMO HOSPITAL: A 4-YEAR OBSERVATION ON CHARACTERISTIC AND RESULT VISUAL OUTCOME OF TRAUMATIC OPTIC NEUROPATHYAFTER STEROID TREATMENT IN KARIADI HOSPITAL UNVEILING OPHTHALMOLOGICAL FINDINGS IN CORNELIA DE LANGE SYNDROME: A RARE CASE REPORT NEUROOPHTHALMOLOGIC MANIFESTATIONS AMONG 195 PATIENTS WITH INTRACRANIAL TUMOR AT NATIONAL REFERRAL HOSPITAL  AN ATYPICAL CASE OF BILATERAL CORNEAL OPACITY: WHAT ARE THE POSSIBLE DIAGNOSIS?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1